| Assessment Status | Rapid Review Complete |
| HTA ID | 26056 |
| Drug | Elinzanetant |
| Brand | Lynkuet® |
| Indication | Elinzanetant (Lynkuet®) for the treatment of moderate to severe vasomotor symptoms (VMS), associated with menopause or caused by adjuvant endocrine therapy (AET) related to breast cancer. |
| Assessment Process | |
| Rapid review commissioned | 07/10/2026 |
| Rapid review completed | 06/11/2026 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that elinzanetant (Lynkuet®) not be considered for reimbursement at the submitted price. |
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here
Further information on the status of this decision may be found here